Premium
P4‐159: MIDLIFE INCIDENT PROLONGED RATE‐CORRECTED QT INTERVAL DOES NOT PREDICT LATE‐LIFE COGNITIVE PERFORMANCE: THE HONOLULU‐ASIA AGING STUDY
Author(s) -
Jackson Jonathan D.,
Gibbons Laura E.,
Thacker Evan,
Suemoto Claudia K.,
Satizabal Claudia L.,
Bettcher Brianne M.,
Mez Jesse,
White Lon R.,
Power Melinda C.
Publication year - 2018
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2018.06.2564
Subject(s) - qt interval , medicine , confounding , quartile , hazard ratio , cognition , myocardial infarction , dementia , cohort , cohort study , proportional hazards model , cardiology , gerontology , confidence interval , psychiatry , disease
>90 years) and performed cox regression analyses. Results:Mean age at inclusion was 72.4 years (SD 7.5, range 65-115 years), 45.7% were male, and median follow-up was 3.7 years (IQR 1.95.7). The follow-up was similar between individuals with and without vascular disorders. During 1.5 million person years of follow-up, 12,362 individuals developed dementia and 41,586 died. Hypertension was associated with lower dementia risk at all ages (Fig 1.). For all other disorders, the risk for dementia was higher at young age than at high age. Hypertension was associated with decreased mortality while all other vascular disorders had an increased risk for death, regardless of age (Fig. 2). Cox regression analyses after correction for age and gender yielded similar results. Conclusions:The risk of vascular disorders for dementia decreases with higher age, in line with population-based studies. Competing risk of mortality may not be an explanation as mortality was decreased in hypertensive individuals and increased in individuals with other vascular pathology regardless of age. Moreover, followup time was similar in individuals with and without vascular disorders. Alternatively, general practitioners may under-diagnose dementia in individuals with vascular diseases or treatment of a clinical diagnosis of vascular disorders may reduce dementia risk. This work has received support from the EU/EFPIA Innovative Medicines Initiative Joint Undertaking EMIF grant agreement no. 115372.